[{"orgOrder":0,"company":"CR Double-Crane Pharmaceuticals Co., Ltd","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ligand and CR Double-Crane Enter Collaboration Agreement to Develop an Oral COVID-19 Therapeutic Using Ligand\u2019s BEPro Technology\u2122","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"China Resources Pharmaceutical Group","sponsor":"Everest Medicines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Everest Medicines Enters into an MOU for Partnership with China Resources Pharmaceutical Group for its mRNA Vaccine Business","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"China Resources Pharmaceutical Group","sponsor":"China Resources Pharmaceutical Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Brii Bio Announces Strategic Partnership with China Resources Pharmaceutical Commercial Group to Advance the Commercialization of Long-acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab\/Romlusevimab Combination, in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Large molecule","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"}]
Find Clinical Drug Pipeline Developments & Deals by China Resources Pharmaceutical Group
Amubarvimab and Romlusevimab are non-competing SARS-CoV-2 monoclonal neutralizing antibodies derived from convalesced COVID-19 patients developed in collaboration with the 3rd People’s Hospital of Shenzhen and Tsinghua University.
Everest’s licensing partner Providence is currently evaluating PTX-COVID19-B in a head-to-head clinical trial against Pfizer-BioNTech’s Comirnaty COVID-19 vaccine. Everest and Providence also plan to initiate a trial in 2022 to further expand the indication of PTX-COVID19-B.
Ligand has preclinical data showing its oral BEPro-enabled COVID-19 antivirals to have a favorable blood concentration profile and generate lower levels of active nucleotide in the kidney, a potential site for toxicity, than other oral and intravenous comparators.